Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody [Immunology and Inflammation]

Anti–CTLA-4 mAb is efficacious in enhancing tumor immunity in humans. CTLA-4 is expressed by conventional T cells upon activation and by naturally occurring FOXP3+CD4+ Treg cells constitutively, raising a question of how anti–CTLA-4 mAb can differentially control these functionally opposing T cell populations in tumor immunity. Here we show that...

http://bit.ly/2FfX8MK